Amadeus Capital is a global technology investor that invests in technology companies at all stages, from seed to venture buyout; they also buy stakes from other investors or founders, to ensure that companies and entrepreneurs have the runway they need to succeed. They invest in a broad variety of sectors including enterprise and infrastructure software, consumer and business services, medical technology and healthcare IT, and cleantech and resource efficiency. It has the imagination to see where new businesses can be created and the technical insight, operational experience and global network to help entrepreneurs make their vision a reality. The Company was founded in 1997 and since has backed more than 130 companies and raised over $1bn for investment.

Amadeus Capital Partners

Parkwalk is a London-based fund management firm.  Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009, anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth. Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow.                                                                                                                 In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.

Parkwalk Advisors

UTEC - The University of Tokyo Edge Capital Partners, is a Japan-based seed/early stage deep-tech venture capital firm associated with academic institutes such as The University of Tokyo. UTEC has over $500M Assets Under Management, and has invested in 100+ companies in Japan, USA, Singapore, India and Europe with a track record of 13 IPOs and 12 successful M&A (as of Mar 2021). UTEC predominantly invests in three deep-tech sectors: a) Healthcare & Life Sciences, b) IT/AI, and c) Physical Sciences & Engineering.

UTEC - The University of Tokyo Edge Capital Partners

Crista Galli Ventures is a venture capital firm that invests in healthtech at Seed and Series A stages.

Crista Galli Ventures

Mint Venture Partners is a global company builder creating startups and venture companies in the biotechnology and healthcare area.  Its create values through commercialization, incubation & acceleration of innovative technologies as well as investment in early-phase startups around the world.  Mint Venture envision to innovate the future health as a global hub of biotech & healthcare industry.

Mint Venture Partners

Charco Neurotech

Charco Neurotech is a medical technology company that develops non-invasive wearable devices.

Charco Neurotech develops non-invasive wearable devices for Parkinson's disease. Its main therapeutic product “CUE1” is a spin-off from Imperial College and uses a specialized vibratory stimulation that aims to provide relief and improve movement symptoms that result from Parkinson’s disease. It can also be used to set medical alerts, customize stimulation settings, and track symptoms through the Charco app. As of November 2021, it was reported that over 5,000 patients across the UK, Europe, and North America were on the waitlist for CUE1 at recommended retail price (RRP) of GBP 295. The company also entered into a tech-driven partnership with the European Parkinson’s Disease Association (EPDA) in November 2021.

A concentration of wealth and a willingness to adopt age-in-place technologies present new opportunities.

Age Tech

Charco Neurotech was founded in 2019 by Lucy Jung, an industrial designer who was inspired to develop assistive devices for Parkinson's after her own experience as a patient. The CUE1 is a small plastic disc with an electric motor that vibrates at a high frequency in a specialized pattern. This pattern, proven through research, can disrupt the overactive brainwaves that cause Parkinson's symptoms, allowing for improved movement.

This Small Wearable Device Reduces Parkinson’s Symptoms

Wearable tech device easing the symptoms of Parkinson’s

CUE1 Device, a Vibrational Therapy to Potentially Treat Parkinson Disease Symptoms: Alistair Mackett, MD

Women in Science: How Charco Neurotech's Lucy Jung is 'restoring joy' for Parkinson's patients

Frequently asked questions

Cambridge Judge Business School

A Non-Invasive Wearable Device for People with Parkinson's

Transforming neurological care with innovation

Neurostimulation Tech

Charco Neurotech sponsors Walk for Parkinson’s 2024 fundraising series

Charco Neurotech develops non-invasive wearable devices for Parkinson's disease. Its main therapeutic product “CUE1” is a spin-off from Imperial College and uses a specialized vibratory stimulation that aims to provide relief and improve movement symptoms that result from Parkinson’s disease. It can also be used to set medical alerts, customize stimulation settings, and track symptoms through the Charco app. As of November 2021, it was reported that over 5,000 patients across the UK, Europe, and North America were on the waitlist for CUE1 at recommended retail price (RRP) of GBP 295. The company also entered into a tech-driven partnership with the European Parkinson’s Disease Association (EPDA) in November 2021.

Honor provides a platform for elderly persons and their families to find home care providers, and is claimed to be one of the largest on-demand home care networks in the US. The company’s key offerings include Home Care, Family Caregiver Resources, and the Honor Family App and Honor Family Care Network for remote monitoring.In August 2021, Honor announced the acquisition of home care provider Home Instead at an undisclosed value. The merged entity was expected to combine for over USD 2.1 billion home care services revenue.&nbsp; Key customers and partnershipsAs of August 2021, Home Instead had around 90,000 caregivers serving at 1,200 locations across the US and global markets. Home Instead acquired UK-based online platform SuperCarers in June 2020. It connects professional caregivers to elderly people seeking at-home care. Prior to the acquisition, SuperCarers had raised a total of GBP 4.9 million (USD 6.6 million).It also partners with the Organisation for the Review of Care and Health Applications (ORCHA) to provide quality assured apps for psychological wellbeing, physical activity, and mental stimulation.

Honor

Eargo specializes in developing hearing aid and related services. Eargo has four products in its lineup: Link by Eargo, Eargo SE, Eargo Neo HiFi, Eargo 6, and Eargo 7. The company’s products are unique due to its design meant to keep the device invisible when plugged in.The products are priced between USD 749 (Link by Eargo) and USD 2,490 (Eargo 7). The Eargo Neo HiFi comes alongside an app and offers connected smart features such as audio personalization and control. The app allows the user to control the audio to suit their surroundings, customize settings, and contact Eargo's licensed hearing professionals for consultation and support.In October 2020, Eargo was listed as a public company and then acquired by Patient Square Capital In October 2023. Via the acquisition, Patient Square Capital acquired all outstanding shares of Eargo—that were not owned by Patient Square—at USD 2.55 per share. Key customers and partnershipsThe company utilizes a business-to-consumer (B2C) online retail strategy compared to traditional business-to-business (B2B) model deployed by other manufacturers who sell their products through clinics. The strategy has proven beneficial through the Covid-19 pandemic as consumer footfall for brick-and-mortar clinics have declined.

Eargo

K4Connect provides technology solutions to residents and staff members in senior living communities through its K4Community platform. The company was co-founded by Scott Moody who sold his fingerprint sensor technology company AuthenTec to Apple for USD 356 million in 2012, which then became the basis for Touch ID.The platform's offerings include digital voice and video communication, and community updates for residents. It also provides smart home automation through the provisioning of plug and play Alexa devices for residents and supports smart thermostats, smart lights, motion sensors, and sleep tracking devices. In addition, community staff members have access to tools for resident surveys, resident and family management, and communications. During the Covid-19 pandemic, the platform also established an expanded video chat service to facilitate resident-to-resident communication, staff requests, yoga classes, and dining room bookings. Further, in March 2020, it partnered with software communications firm Bandwidth to introduce a hotline for staff and residents as a means of keeping all parties up to date with community information.The platform is built on the company’s patented operating system, FusionOS. The company claims that FusionOS is an advanced multi-modal edge-cloud architecture, the first of its kind in the senior living industry. Residents and staff can access the platform using a smartphone app or pre-provisioned tables in the living communities priced on a per-resident basis.As of July 2020, the platform served over 800 independent and assisted living senior living communities across the US. The platform serves over 29,000 users at more than 125 senior living communities across 27 customers as of February 2020, more than doubling its users from 2018, which it expects to repeat in 2020. The company has established channel partnerships with Allbridge (a data, video and voice solution provider for senior living) in July 2020, and Eskaton (a senior services provider) and White Horse Village (a continuing care retirement community) in May 2019. It collaborated with GlobalLogic (a digital product engineering company) in July 2020 to expedite the development schedule of its K4Community Plus app in response to Covid-19.

K4Connect

CarePredict was founded by Former IBM consultant and tech veteran, Satish Movva, and produces Tempo smart wearables for the elderly community. Using machine learning (ML), the company claims the app can reduce the chance of a fall, and predict urinary tract infections (UTIs) and depression ahead of a clinical diagnosis. The device aims to assist caregivers in taking preventive action by detecting activities and behaviors which are precursors to health declines. The data from the device can also be shared with family members.The company generates revenue from device sales and subscriptions. Independent research conducted in September 2020 indicated that facilities using CarePredict’s wearables reported 40% fewer hospitalizations 69%, lower fall rates, 67% increased length of stay, and a 37% improved staff response rate than facilities that did not use CarePredict.The company expanded its operations in 2018 through its acquisition of WiseWare, a company selling activity-tracking jewelry for older users. In April 2020, it launched the PinPoint contact-tracing tools to mitigate the spread of Covid-19.Key customers and partnershipsIn February 2021, the company announced its partnership with Middle Alabama Area Agency on Aging (M4A). M4A is the agency behind the “Providing Alzheimer's N' Dementia Assistance” (PANDA) project. The company will be the first tech platform to be part of the project and will provide caregivers assistance in remote monitoring and preventive care using its smart wearables.

CarePredict

Eversound develops wireless headphone systems to enhance the level of engagement and social interaction for the elderly living in assisted living or memory care centres. The platform provides a library of programmed content on a variety of topics. The headphone system can be used to communicate with caregivers, during group events, family visits, and for music therapy. The headphones are equipped with a wireless transmitter and volume controls. It connects to external audio sources such as community A/V systems, televisions, and audio devices.The product was unveiled in May 2016. In a subsequent six month study conducted by LCB Senior Living community, group events leveraging the Eversound system resulted in an 18% reduction of residents falling asleep and a 28% increase in engagement during group events. In December 2016, the company expanded to 18 states across the US.In March 2020, as a part of its Covid-19 response, the company launched a live streamed, interactive content service to help seniors combat isolation. Further, as in-person visits at assisted living communities were interrupted due to the Covid-19 pandemic, the use of Eversound’s visitation package proved to be crucial for socially distanced in-person visits. Key customers and partnershipsAs of December 2020, the company’s product is being used in more than 700 senior living communities across the US. Its clients include senior living communities such as Brightview, Commonwealth, and Oakmont. In addition, Eversound has established partnerships with senior living communities (such as The Arbor Company, Bridges by EPOCH, Christian Horizons, and Kisco) to roll out its devices for family visitations, and programmable and live streamed content.

Eversound

Tech-enabled equipment or companionship services that help elderly people function independently.

Platforms that match seniors with home care providers as well as app-based products to facilitate communication between senior families and caregivers

Tech-enabled products used to diagnose, prevent, and treat conditions common among seniors.

Remote monitoring, medical diagnosis, communication, and coordination between caregivers and families of the elderly.

Platforms that help seniors interact socially and communicate with others.

Platforms that help seniors and their families plan and make arrangements to settle the senior’s estates and affairs in the event of death.

Companies that use GenAI as a core part of their product offering for Age Tech

Offers digital platforms that support the wellness of the senior population

Age Tech providers incorporate GenAI to enhance both seniors’ and caregivers’ experiences

Many devices that help seniors operate independently and receive remote treatment use IoT

Some companies use VR to help treat seniors with conditions such as isolation and dementia

Charco Neurotech was founded in 2019 by Lucy Jung, an industrial designer who was inspired to develop assistive devices for Parkinson's after her own experience as a patient. The CUE1 is a small plastic disc with an electric motor that vibrates at a high frequency in a specialized pattern. This pattern, proven through research, can disrupt the overactive brainwaves that cause Parkinson's symptoms, allowing for improved movement.
The CUE1 attaches to the user's sternum using medical adhesive and is relatively inexpensive compared to other treatments like deep brain stimulation implants. Over 2,000 people in the UK are currently using the CUE1, with a waiting list of almost 20,000 across 120 countries as of March 2024. Charco has raised over USD 10 million in funding and grants, employing around 38 people across the UK, South Korea, and the US.
The device is accompanied by a smartphone app that enables users to personalize the stimulation settings and track their symptoms. Charco aims to obtain regulatory approvals for the CUE1 to be prescribed through healthcare systems like the NHS. In April 2023, Addenbrooke's Hospital in Cambridge became the first hospital to trial the device on inpatients with Parkinson's.
Key customers and partnerships
As of August 2023, over 1,700 people are benefiting from the CUE1 in the UK, and there is a waiting list of over 17,000 people worldwide. Charco has partnered with Dr. Alistair Mackett, a consultant geriatrician at Cambridge University Hospitals, to conduct trials and research on the device's effectiveness.

Aleva Neurotherapeutics is a medical device company specializing in deep brain stimulation (DBS) systems for treating neurological disorders such as Parkinson's disease and essential tremor. Based in Lausanne, Switzerland, the company was founded as a spin-off from the Swiss Federal Institute of Technology. Aleva pioneered the development of directional DBS leads with its flagship product, the directSTIM DBS system. This technology aims to deliver more precise electrical stimulation to targeted areas of the brain, potentially improving therapeutic benefits and reducing side effects compared to traditional omnidirectional DBS leads.
The directSTIM system features a novel 12-electrode lead design based on microelectromechanical systems (MEMS) technology. This allows for smoother electrode surfaces and customized shapes optimized for implantation in the brain. The system also incorporates 24 independent current sources, enabling greater flexibility in programming and personalizing stimulation patterns to each patient's unique needs. In May 2024, Aleva received CE marking for the directSTIM system, allowing its commercial launch in Europe.
Aleva's expertise in DBS technology is reflected in its robust intellectual property portfolio, comprising 13 patent families and 90 granted patents related to DBS for neurological and psychiatric disorders. The company aims to transform DBS therapy by combining advanced technologies with shared clinical data to improve surgical experiences and patient outcomes.

Aleva Neurotherapeutics

BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The company has developed Deep Transcranial Magnetic Stimulation (Deep TMS), a proprietary technology that uses magnetic pulses through a patented H-coil helmet to stimulate deeper and broader brain regions associated with various conditions.
Deep TMS received FDA clearance for treating major depressive disorder (MDD) in 2013, making BrainsWay the first and only TMS company with clinical evidence demonstrating efficacy for this indication. In 2018, the technology obtained FDA clearance for treating obsessive-compulsive disorder (OCD), and in 2021, it was cleared as an aid for short-term smoking cessation.
The Deep TMS treatment is administered through a series of daily sessions over four to six weeks, with each session lasting around 20 minutes. It has been investigated in over 30 randomized clinical trials worldwide, demonstrating its safety and effectiveness. As of April 2021, BrainsWay announced that 100,000 patients have been treated globally with Deep TMS.
In addition to the FDA-cleared indications, BrainsWay is conducting ongoing or planned clinical trials exploring Deep TMS for various psychiatric, neurological, and addiction disorders. The company's commitment to clinical research and building upon its substantial body of evidence positions it as a leader in advancing neuroscience through non-invasive solutions.

Brainsway

Cala Health is a bioelectronic medicine company that has developed the Cala kIQ system, a wearable neuromodulation device that delivers transcutaneous afferent patterned stimulation (TAPS) therapy for the relief of hand tremors in adults with essential tremor and Parkinson's disease. The Cala kIQ system comprises a stimulator, a band with integrated electrodes, and a base station. It utilizes a calibrated TAPS output pattern adjusted to match the patient's unique tremor frequency, providing personalized stimulation to the median and radial nerves of the wrist.
The Cala kIQ system received 510k clearance from the US Food and Drug Administration (FDA) in November 2022 and was launched for human use in June 2023. The device offers treatment sessions of 40 minutes, with a wristband life of 90 days and a shelf life of three months. Patients can review their therapy session results through the MyCala.com patient portal and share them with healthcare providers.
Cala Health has reported positive clinical data demonstrating the effectiveness of TAPS therapy in reducing tremors and improving activities of daily living for essential tremor patients. The company has secured reimbursement and coding from various commercial and government payors, including Medicare, to improve patient access to the therapy.

Cala Health

Cardionomic is a medical device company based in Minneapolis that has developed the Cardiac Pulmonary Nerve Stimulation (CPNS) System, an investigational device designed to treat patients suffering from acute decompensated heart failure (ADHF). The CPNS System consists of a stimulation console and an endovascular catheter that delivers targeted stimulation to the cardiac plexus located in the right pulmonary artery.
The company's approach is founded on the principle that stimulating the autonomic nerves improves a patient's clinical condition by triggering a rebalancing of the autonomic system, shifting it from an imbalanced state into a cycle that enhances the patient's condition even after the therapy is completed. The CPNS System has demonstrated the ability to increase cardiac contractility without significantly affecting heart rate in heart failure patients with reduced ejection fraction.
In January 2024, Cardionomic announced the completion of enrollment in the STIM-ADHF and STOP-ADHF pilot studies, which evaluated the safety and performance of the CPNS System in treating ADHF patients. A total of 35 patients were treated across seven countries. Preliminary results suggest that the CPNS therapy may address the unmet need for more effective treatment options for hospitalized heart failure patients. The pooled data from these studies is planned for publication in early 2024.
The CPNS System leverages engineered electrode surfaces from Pulse Technologies, Inc. to deliver durable electrochemical performance for the neural and cardiac interfacing applications.

Cardionomic

Companies that offer solutions for pain management, neuropathies, and related disorders and migraines.

Companies that provide solutions for Parkinson's disease, epilepsy, and speech and movement disorders.

Companies that offer treatments for depression, Alzheimer's, and other mental health-related disorders.

Companies that offer solutions for heart-related medical issues such as acute decompensated heart failure and high blood pressure.

Companies that offer solutions for urinary or fecal incontinence, autoimmune diseases and other functional impairments

Companies that offer solutions for hearing or vision impairment, sleep-related conditions, and other disorders, including obesity treatments.

Charco Neurotech

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless